BRPI0812384A2 - Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 - Google Patents
Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21Info
- Publication number
- BRPI0812384A2 BRPI0812384A2 BRPI0812384-5A2A BRPI0812384A BRPI0812384A2 BR PI0812384 A2 BRPI0812384 A2 BR PI0812384A2 BR PI0812384 A BRPI0812384 A BR PI0812384A BR PI0812384 A2 BRPI0812384 A2 BR PI0812384A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- fgf21
- diagnostic
- methods associated
- disease
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93951207P | 2007-05-22 | 2007-05-22 | |
PCT/US2008/006481 WO2008153705A2 (en) | 2007-05-22 | 2008-05-20 | Methods of treating, diagnosing and detecting fgf21-associated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0812384A2 true BRPI0812384A2 (pt) | 2014-12-02 |
Family
ID=39739850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0812384-5A2A BRPI0812384A2 (pt) | 2007-05-22 | 2008-05-20 | Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110002845A1 (pt) |
EP (1) | EP2152737A2 (pt) |
JP (1) | JP2010529954A (pt) |
KR (1) | KR20100017169A (pt) |
CN (1) | CN101679501A (pt) |
AU (1) | AU2008262450A1 (pt) |
BR (1) | BRPI0812384A2 (pt) |
CA (1) | CA2687746A1 (pt) |
EA (1) | EA200901550A1 (pt) |
MX (1) | MX2009012625A (pt) |
WO (1) | WO2008153705A2 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
PE20120021A1 (es) | 2008-10-10 | 2012-02-10 | Amgen Inc | Mutantes fgf21 |
CN107188950B (zh) | 2009-05-05 | 2021-09-28 | 安姆根有限公司 | Fgf21突变体及其用途 |
MX2011011815A (es) | 2009-05-05 | 2012-01-27 | Amgen Inc | Mutantes fgf21 y usos de los mismos. |
US20120076729A1 (en) * | 2009-06-04 | 2012-03-29 | Novartis Ag | Methods of treating cancers |
EP2443145A1 (en) | 2009-06-17 | 2012-04-25 | Amgen, Inc | Chimeric fgf19 polypeptides and uses thereof |
MX2012004303A (es) * | 2009-10-15 | 2012-06-25 | Genentech Inc | Factores de crecimiento de fibroblasto quimericos con especificacion de receptor alterada. |
EP2679234A3 (en) | 2009-12-02 | 2014-04-23 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
KR101900962B1 (ko) * | 2010-04-09 | 2018-09-20 | 큐알엔에이, 인크. | 섬유아세포 성장 인자 21 (fgf21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (fgf21) 관련된 질환의 치료 |
CA2796055A1 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | Human fgf receptor and .beta.-klotho binding proteins |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012045082A2 (en) | 2010-10-01 | 2012-04-05 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
CN102296110B (zh) * | 2011-07-18 | 2016-08-10 | 西北农林科技大学 | 一种检测黄牛fgf21基因单核苷酸多态性的方法 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN107001461A (zh) | 2014-09-16 | 2017-08-01 | 瑞泽恩制药公司 | 抗胰高血糖素抗体及其使用方法 |
TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗angptl8抗體及其用途 |
CN107449715B (zh) * | 2016-05-30 | 2021-01-22 | 康建胜 | 活细胞胞内代谢分析仪及其分析方法 |
CN110036029A (zh) | 2016-11-17 | 2019-07-19 | 瑞泽恩制药公司 | 用抗angptl8抗体处理肥胖的方法 |
US20200000880A1 (en) * | 2017-02-01 | 2020-01-02 | Children's Medical Center Corporation | Fgf21 compositions for treatment or prevention of neovascularization of the eye and methods therefor |
JP7022145B2 (ja) * | 2017-04-04 | 2022-02-17 | ジェネンテック, インコーポレイテッド | 線維芽細胞活性化タンパク質(fap)によって認識される基質とその使用方法 |
JP7066540B2 (ja) * | 2018-06-14 | 2022-05-13 | 株式会社日立製作所 | デジタルpcrの測定方法および測定装置 |
CN110279847B (zh) * | 2019-05-17 | 2023-04-14 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Fgf21在制备促进超长随意皮瓣存活的药物中的应用 |
CN110257512A (zh) * | 2019-05-20 | 2019-09-20 | 上海交通大学医学院 | 用于luminal型和HER2型乳腺癌诊断、治疗及预后的标志物和组合物 |
CN111420030B (zh) * | 2020-05-12 | 2021-01-29 | 江南大学 | Fgf21在制备用于治疗结直肠癌药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001018209A1 (en) * | 1999-09-10 | 2001-03-15 | Curagen Corporation | Fibroblast growth factor polypeptide and nucleic acids encoding same |
US6716626B1 (en) * | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
AU1628101A (en) * | 1999-11-22 | 2001-06-04 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
EP1666491A1 (en) * | 2000-06-02 | 2006-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2003270424A1 (en) * | 2002-09-09 | 2004-03-29 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
WO2006065582A2 (en) * | 2004-12-14 | 2006-06-22 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
EP1846019A2 (en) * | 2005-01-21 | 2007-10-24 | Eli Lilly And Company | Method for treating cardiovascular disease |
JP2006246823A (ja) * | 2005-03-11 | 2006-09-21 | Kyoto Univ | 造血因子としてのFgf21の使用 |
-
2008
- 2008-05-20 BR BRPI0812384-5A2A patent/BRPI0812384A2/pt not_active Application Discontinuation
- 2008-05-20 US US12/600,853 patent/US20110002845A1/en not_active Abandoned
- 2008-05-20 MX MX2009012625A patent/MX2009012625A/es not_active Application Discontinuation
- 2008-05-20 EA EA200901550A patent/EA200901550A1/ru unknown
- 2008-05-20 CN CN200880017036A patent/CN101679501A/zh active Pending
- 2008-05-20 WO PCT/US2008/006481 patent/WO2008153705A2/en active Application Filing
- 2008-05-20 JP JP2010509368A patent/JP2010529954A/ja active Pending
- 2008-05-20 EP EP08754594A patent/EP2152737A2/en not_active Withdrawn
- 2008-05-20 AU AU2008262450A patent/AU2008262450A1/en not_active Abandoned
- 2008-05-20 CA CA002687746A patent/CA2687746A1/en not_active Abandoned
- 2008-05-20 KR KR1020097024179A patent/KR20100017169A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2010529954A (ja) | 2010-09-02 |
CN101679501A (zh) | 2010-03-24 |
WO2008153705A3 (en) | 2009-03-05 |
CA2687746A1 (en) | 2008-12-18 |
EA200901550A1 (ru) | 2010-10-29 |
MX2009012625A (es) | 2009-12-07 |
US20110002845A1 (en) | 2011-01-06 |
KR20100017169A (ko) | 2010-02-16 |
AU2008262450A1 (en) | 2008-12-18 |
WO2008153705A2 (en) | 2008-12-18 |
EP2152737A2 (en) | 2010-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0812384A2 (pt) | Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 | |
BRPI0917567A2 (pt) | tratamento de doença respiratória | |
BRPI0813212A2 (pt) | Métodos de tratamento de doenças e distúrbios mediados por serotonina | |
BRPI0814889A2 (pt) | tratamento com ligantes alfa7-seletivos. | |
FR2921499B1 (fr) | Structure orientable de type catheter ou endoscope | |
BRPI0722004A2 (pt) | Posto de saúde. | |
BRPI0813364A2 (pt) | Métodos de diagnóstico e tratamento de câncer. | |
BRPI0922322A2 (pt) | endoscópio com uma porção curvada | |
BRPI0807896A2 (pt) | Fórceps bipolares não-aderentes. | |
BRPI0816794A2 (pt) | Tratamento pós-colheita. | |
BRPI0923409A2 (pt) | cabeça de escova de dentes, e, escova de dentes. | |
BR112012002124A2 (pt) | tratamento da doença de crohn com laquinimode. | |
BRPI0815889A2 (pt) | Análise do perfil de glicosilação. | |
PT2376537T (pt) | Anticorpos humanos contra fator tecidual humano | |
BRPI0822572A2 (pt) | Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações | |
IT1391555B1 (it) | Apparato trattamento extracorporeo sangue | |
DK1863899T3 (da) | Hudbehandlingspræparater | |
BRPI0820101A2 (pt) | Combinação, e, aparelho que cobre a cabeça de estetoscópio | |
ATE494839T1 (de) | Gewebeentnahme | |
BRPI0810559A2 (pt) | Macadores de doenças | |
DE602007001361D1 (de) | Sphinkterotom mit Zweifachkrümmung | |
DK2173831T3 (da) | Brøndbehandling | |
IL199807A0 (en) | Biometric diagnosis | |
EP2304437A4 (en) | DIAGNOSTIC AID SPECIFIC TO A DISEASE | |
BRPI0822381A2 (pt) | Agulha de coleta de sangue com sinalização |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |